Posted 23 January, 2023
Cadrenal Therapeutics, Inc. IPO completed
IPO completed detected for ticker Nasdaq:CVKD in a 424B4 filed on 23 January, 2023.
This is the initial public offering of our common stock and no public market currently exists for our common stock.
Don't know how to trade IPO completion? Read Initial Public Offerings.
Overview of Cadrenal Therapeutics, Inc.
Health Care/Life Sciences • Pharmaceuticals
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham on January 25, 2022 and is headquartered in Ponte Vedra, FL.Market Cap
$8.66M
View Company Details
$8.66M
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.